How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Do you agree on the proposal for withdrawing this technology appraisal? If not, please can you state why you disagree.

  • Question on Consultation

    Are you aware of any implications for UK clinical practice on withdrawing this technology appraisal? If so, please describe.

2025 withdrawal proposal for pharmalgen for the treatment of bee and wasp venom allergy (TA246)

Open for comments Open until   Request commenting lead permission

We have updated this service so that members of the same organisation can now collaborate on a joint online response.

Read our blog to learn more.

System impact

NICE system intelligence on drug usage indicates that pharmalgen is no longer used in the UK. The manufacturer confirmed that pharmalgen was phased out and the UK license withdrawn due to the introduction of a newer product for the treatment of bee and wasp venom allergy (Alutard SQ).